Canada NewsWire
HAMILTON, ON and BOSTON , Nov. 8, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences.
- Jefferies London Healthcare Conference – The Company fireside chat presentation will take place on Thursday, November 16, 2023 at 9:00 a.m. GMT . Presenting on behalf of Fusion will be Chief Executive Officer John Valliant , Ph.D.
- Piper Sandler 35 th Annual Healthcare Conference – The Company will participate in the "Radiopharmaceuticals Panel" taking place on Wednesday, November 29, 2023 at 10:00 a.m. ET . Presenting on behalf of Fusion will be Chief Scientific Officer Christopher Leamon , Ph.D.
Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts . A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen ( PSMA ) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies ( TATs ) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors ( DDRis ) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET . Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA ® ( pembrolizumab ) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs , the Company has signed strategic actinium supply agreements with TRIUMF , Niowave , Inc. and BWXT Medical.
Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com
SOURCE Fusion Pharmaceuticals
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2023/08/c7284.html